Anthropic has launched Claude of Life Sciences that uses artificial intelligence in advancing scientifific discovery. Image by Anthropoc/newsroom
Anthropic on Monday announced a new service called Claude of Life Sciences that uses artificial intelligence in efforts to advance scientific discovery.
This is the San Francisco-based tech company’s first formal entry into life sciences research.
Digital tools will allow researchers to use Claude to make new discoveries through literature reviews to developing hypotheses, analyzing data, drafting regulatory submission, Anthropic said.
“Now is the threshold moment for us where we’ve decided this is a big investment area,” Eric Kauderer-Abrams, who was hired a few months ago as head of biology and life science for Anthropic, told CNBC in an interview Monday. “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding.”
Anthropic has developed a family of large language models through Claude.
On Sept. 29, Anthropic launched its newest model, Caude Sonnet 4.5, which is “significantly better” at life sciences, including laboratory protocols.
Previously, scientists used Claude of individual tasks, including writing codes for statistical analysis or summarizing papers.
“Now, our goal is to make Claude capable of supporting the entire process, from early discovery through to translation and commercialization,” the company said. “To do this, we’re rolling out several improvements that aim to make Claude a better partner for those who work in the life sciences, including researchers, clinical coordinators and regulatory affairs managers.”
The company said the new Claude version is better at several life science tasks.
“What I’m chasing is to bring to biologists the experience that software engineers have [with code generation],” Kauderer-Abrams said. “You can sit down with Claude and brainstorm ideas, generate hypotheses together.”
Before the launch, Kauderer-Abrams said researchers already had working on models to help with isolated parts of the life sciences process.
Anthripic is working with several involved in life sciences, including Benchling, PubMed, 10x Genomics and Synapse.or. Anthropic has also partnered with companies to help life sciences organizations adopt AI, including Caylent, KPMG, Deloitte and cloud providers AWS and Google Cloud, the company said.
“We’re willing and enthusiastic about doing that grind to make sure that all the pieces come together,” Kauderer-Abrams said.
Benchling, founded in 2012, provides a unified, cloud-based platform for more than 1,300 biotech companies worldwide
“AI in R&D only works through an ecosystem,” Ashu Singhal, co-founder and president of Benchling, said in a newsrelease. “Anthropic is doing this right, bringing together the best technologies while putting access, governance, and interoperability first. For more than a decade, scientists have trusted us as the source of truth for experimental data and to modernize their workflows. Now we’re building AI that powers this next chapter of R&D.”
PubMed provides access to millions of biomedical research articles and clinical studies.
BioRender connects Claude to its library of vetted scientific figures icons and templates.
Scholar Gateway, which developed by Wiley, provides access to authoritative, peer-reviewed scientific content.
Synapse.org allows scientists to share and analyze data together for public or private projects.
And 10x Genomics allows researchers to conduct single cell and spatial analysis.
In a video demonstration, the company shows how a scientist was able to carry out lab’s data, then generate a summary and tables of key differences. The scientist was able to generate a report that could be included in regulatory process.
We’re building tools to support research in the life sciences, from early discovery through to commercialization.
With Claude for Life Sciences, we’ve added connectors to scientific tools, Skills, and new partnerships to make Claude more useful for scientific work. pic.twitter.com/NxXY1LngjX— Anthropic (@AnthropicAI) October 20, 2025
Anthropic said the process can take minutes instead of days.
“We’re here to make sure that this transformation happens and that it’s done responsibly,” Kauderer-Abrams said, noting it can’t be used to develop weapons.
Kauderer-Abrams noted the model is designed to cut down clinical trials from three years to one month.
Novo Nordisk already used Anthropic’s AI model to cut clinical study documentation from more than 10 weeks to 10 minutes, the Financial Times reported. Sanofi said the majority of its employees use Claude every day.
In February, Google unveiled “co-scientist,” tool that could help scientists come up with new hypotheses. Last open Gemma model’s had helped discover a new potential cancer therapy pathway.
Claude for Life Sciences is available through Claude.com and on the AWS Marketplace. Google Cloud Marketplace availability is coming soon, the company said.
Anthropic, a public AI research and development company headquartered in San Francisco, was founded in 2021 by seven OpenAI leaders and researchers who left because of disagreements over safety policies. OpenAI is a rival company.
In 2023, Amazon invested $4 billion and Google $2 billion in the company.
